AU2022221336A1 - OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS - Google Patents

OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS Download PDF

Info

Publication number
AU2022221336A1
AU2022221336A1 AU2022221336A AU2022221336A AU2022221336A1 AU 2022221336 A1 AU2022221336 A1 AU 2022221336A1 AU 2022221336 A AU2022221336 A AU 2022221336A AU 2022221336 A AU2022221336 A AU 2022221336A AU 2022221336 A1 AU2022221336 A1 AU 2022221336A1
Authority
AU
Australia
Prior art keywords
water
hco
mmol
condition
under
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022221336A
Other languages
English (en)
Inventor
Richard T. Beresis
John Cijiang He
Kyung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Original Assignee
Icahn School of Medicine at Mount Sinai
US Department of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School of Medicine at Mount Sinai, US Department of Veterans Affairs filed Critical Icahn School of Medicine at Mount Sinai
Publication of AU2022221336A1 publication Critical patent/AU2022221336A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2022221336A 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS Pending AU2022221336A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163147859P 2021-02-10 2021-02-10
US63/147,859 2021-02-10
PCT/US2022/015767 WO2022173795A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Publications (1)

Publication Number Publication Date
AU2022221336A1 true AU2022221336A1 (en) 2023-08-24

Family

ID=82837244

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022221336A Pending AU2022221336A1 (en) 2021-02-10 2022-02-09 OXADIAZOLYL DIHYDROPYRANO[2,3-b]PYRIDINE INHIBITORS OF HIPK2 FOR TREATING KIDNEY FIBROSIS

Country Status (9)

Country Link
US (1) US20250179084A1 (https=)
EP (1) EP4291183B1 (https=)
JP (1) JP2024506387A (https=)
KR (1) KR20230154194A (https=)
CN (1) CN117479934A (https=)
AU (1) AU2022221336A1 (https=)
CA (1) CA3210658A1 (https=)
MX (1) MX2023009323A (https=)
WO (1) WO2022173795A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240051965A1 (en) * 2022-08-05 2024-02-15 Icahn School Of Medicine At Mount Sinai Oxygen-containing heterocyclic compound and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2069335T3 (pl) * 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
PE20091339A1 (es) * 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
EP2210890A1 (en) * 2009-01-19 2010-07-28 Almirall, S.A. Oxadiazole derivatives as S1P1 receptor agonists
ES2907624T3 (es) * 2017-01-06 2022-04-25 Icahn School Med Mount Sinai Inhibidores de oxadiazol de HIPK2 para el tratamiento de la fibrosis renal
JP7252908B2 (ja) * 2017-06-14 2023-04-05 トレベナ・インコーポレイテッド Ｓ１ｐ１活性を調節するための化合物およびその使用法

Also Published As

Publication number Publication date
MX2023009323A (es) 2023-12-14
WO2022173795A1 (en) 2022-08-18
US20250179084A1 (en) 2025-06-05
CN117479934A (zh) 2024-01-30
JP2024506387A (ja) 2024-02-13
EP4291183A1 (en) 2023-12-20
EP4291183B1 (en) 2026-04-08
KR20230154194A (ko) 2023-11-07
EP4291183A4 (en) 2025-01-08
CA3210658A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
AU2020384121B2 (en) GLP-1 receptor agonist and use thereof
KR102485620B1 (ko) Acc 억제제 및 그의 고체 형태를 제조하는 방법
CN115867556B (zh) Lpa受体拮抗剂及其用途
CN116354988A (zh) 四环类化合物及其医药用途
KR20230035692A (ko) 티에노피리미딘디온 acc 억제제의 고체 형태 및 그의 제조 방법
EP3983384A1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
KR20240131460A (ko) 비-융합된 티오펜 유도체 및 이의 용도
PT2660239T (pt) Compostos químicos como intermediários sintéticos
JP2015520186A (ja) 増殖性疾患の治療にキナーゼ阻害剤として有用なジヒドロナフチリジン及び関連化合物
KR20160006207A (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
CN116120296A (zh) 一种多环化合物、包含其的药物组合物、其制备方法及其用途
HUE024989T2 (en) Azaindole derivatives as ABI and SRC protein kinase inhibitors
JP2018138609A (ja) ナフチリジンジオン誘導体
EP4074699A1 (en) Compound as cyclin-dependent kinase 9 inhibitor and use thereof
JP7129728B2 (ja) Ｆｇｆｒ４阻害剤として使用される縮環誘導体
EP4291183B1 (en) Oxadiazolyl dihydropyrano[2,3-b]pyridine inhibitors of hipk2 for treating kidney fibrosis
JP2017516829A (ja) ピリドピリミジンジオン誘導体
KR102603436B1 (ko) 방향족 화합물, 약학적 조성물 및 그 용도
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
CN110054622A (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
CN113045569A (zh) 用作ret激酶抑制剂的化合物及其应用
CA3083331A1 (en) Imidazopyridine derivatives and the use thereof as medicament
CN115215787A (zh) 生长抑素受体5拮抗剂及其用途
TW202430505A (zh) 萘醯胺類化合物、其製備方法及其應用